Supernus Pharmaceuticals SUPN AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's AFS securities?
- Supernus Pharmaceuticals (SUPN) reported AFS securities of $199.37M in Q1 2026.
- How has Supernus Pharmaceuticals's AFS securities changed year-over-year?
- Supernus Pharmaceuticals's AFS securities decreased by 42.7% year-over-year, from $347.74M to $199.37M.
- What is the long-term trend for Supernus Pharmaceuticals's AFS securities?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's AFS securities has grown at a -8.3% compound annual growth rate (CAGR), from $255.41M to $180.22M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.